Press release on behalf of Merck

  Real-World Data Further Support Efficacy of Dimethyl Fumarate in Newly Diagnosed and Early Switch Patients MS Patients with High Disease Activity Benefit from Early and Continued Natalizumab Treatment. Biogen have announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may […]

Results from the first randomised, controlled trial investigating the efficacy and safety of APO-go®/MOVAPO® (apomorphine) subcutaneous infusion in Parkinson’s disease (PD) patients whose motor symptoms are not controlled by other therapies – the TOLEDO study – were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, USA, […]

Podcast: Michele Hu discusses with Parkinson’s UK how her work as a neurologist and a researcher drives forward the search for better treatments and a cure

Vital NHS services that people living with MS rely on are facing increasing pressures which could lead to inequities in care, according to a major new report published by the MS Trust. Evidence for MS specialist services, the findings from the MS Trust’s three-year GEMSS evaluation project, provides an unprecedented insight into the state of […]